Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author

A. Affleck (Lead / Corresponding author), A. Goudie, R. Smith

    Research output: Contribution to journalLetter

    8 Downloads (Pure)

    Abstract

    There appears to be some overlap in pathogenetic mechanisms between psoriasis and idiopathic pulmonary fibrosis e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly idiopathic pulmonary fibrosis) independent of previous or concomitant exposure to immunosuppressant therapy. This article is protected by copyright. All rights reserved.

    Original languageEnglish
    Pages (from-to)593-594
    Number of pages2
    JournalClinical and Experimental Dermatology
    Volume44
    Issue number5
    Early online date24 Apr 2019
    DOIs
    Publication statusPublished - 1 Jul 2019

    Keywords

    • Humans
    • Idiopathic Pulmonary Fibrosis
    • Immunosuppressive Agents
    • Methotrexate
    • Psoriasis

    Fingerprint Dive into the research topics of 'Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author'. Together they form a unique fingerprint.

  • Cite this